Peter Attia· MD
to my eye rapamycin is the only drug you've started at 20 months of age i know you repeated it once at 20 but that's that's a big ask of a drug right well i'm pleased that it worked
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
to my eye rapamycin is the only drug you've started at 20 months of age i know you repeated it once at 20 but that's that's a big ask of a drug right well i'm pleased that it worked
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
by the time you're 20 months of age in a mouse which is sort of like 55 or 60 years old in a person something like that not yet at the median survival but getting pretty close that's damage will have occurred that's irreversible collagen cross-linking and death of some brain cells and uh clogging of the arteries or whatever is going to get you it started already by the time you're in your 50s and 60s or for mous by the time you're in your 20th or 21st month but apparently there's still some further stages of that process that occur afterwards after we started to administer the drug at 20 months of age which are dependent on aging and the drug inhibits
starting as is 20 months of age does not diminish the um ability of the drug to extend lifespan this is just really remarkable
apparently there's still some further stages of that process that occur afterwards after we started to administer the drug at 20 months of age which are dependent on aging and the drug inhibits
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.